Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Altimmune, Inc.ALT · Entity 5349 | Director | May 01, 2026 | May 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Altimmune, Inc.
Report date May 01, 2026 · Filed May 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (option to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.82 · Expires 2036-05-01 | Direct | 48,800 |
Reported balance
After 2026-05-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-01 · Grant · Acquired 48,800 · Balance 48,800 F1: The options were granted pursuant to the Company's non-employee director compensation policy. F2: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following May 1, 2026, subject to the reporting person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options were granted pursuant to the Company's non-employee director compensation policy.
F2: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following May 1, 2026, subject to the reporting person's continued service through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 01, 2026 Filed May 1, 2026 20:05 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 48,800 | $0.00 Strike: $2.82 | $0.00 |
DisclosureSEC source: 0001201196-26-000002 · form4-05012026_080555.xml · derivative · entry 1 SAYARE MITCHEL · CIK 0001201196 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,800 Underlying: Common Stock, par value $0.0001 · 48,800 shares Expires 2036-05-01 F1 · security: The options were granted pursuant to the Company's non-employee director compensation policy. F2 · derivative.exercise_date: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following May 1, 2026, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| September 25, 2025 Filed Sep 29, 2025 20:14 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 48,800 | $0.00 Strike: $3.92 | $0.00 |
DisclosureSEC source: 0001104659-25-094488 · tm2527377-3_4seq1.xml · derivative · entry 1 SAYARE MITCHEL · CIK 0001201196 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,800 Underlying: Common Stock, par value $0.0001 · 48,800 shares Expires 2035-09-25 F1 · derivative.exercise_date: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following September 25, 2025, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| September 26, 2024 Filed Sep 30, 2024 22:35 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 34,900 | $0.00 Strike: $6.81 | $0.00 |
DisclosureSEC source: 0001104659-24-104441 · tm2425266-5_4seq1.xml · derivative · entry 1 SAYARE MITCHEL · CIK 0001201196 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,900 Underlying: Common Stock, par value $0.0001 · 34,900 shares Expires 2034-09-26 F1 · derivative.exercise_date: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following September 26, 2024, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| September 28, 2023 Filed Sep 29, 2023 21:00 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 26,100 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001104659-23-105390 · tm2327241-3_4seq1.xml · derivative · entry 1 SAYARE MITCHEL · CIK 0001201196 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,100 Underlying: Common Stock, par value $0.0001 · 26,100 shares Expires 2033-09-28 F1 · derivative.exercise_date: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following September 28, 2023, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| September 29, 2022 Filed Oct 1, 2022 01:20 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 23,500 | $0.00 Strike: $12.62 | $0.00 |
DisclosureSEC source: 0001104659-22-104776 · tm2227177-2_4seq1.xml · derivative · entry 1 SAYARE MITCHEL · CIK 0001201196 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,500 Underlying: Common Stock, par value $0.0001 · 23,500 shares Expires 2032-09-29 F1 · derivative.exercise_date: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following September 29, 2022, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| September 23, 2021 Filed Sep 25, 2021 00:47 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 24,100 | $0.00 Strike: $15.44 | $0.00 |
DisclosureSEC source: 0001104659-21-119488 · tm2128463-6_4seq1.xml · derivative · entry 1 SAYARE MITCHEL · CIK 0001201196 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,100 Underlying: Common Stock, par value $0.0001 · 24,100 shares Expires 2031-09-23 F1 · derivative.exercise_date: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following September 23, 2021, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| September 24, 2020 Filed Sep 28, 2020 22:00 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 25,500 | $0.00 Strike: $12.03 | $0.00 |
DisclosureSEC source: 0000899243-20-026414 · doc4.xml · derivative · entry 1 SAYARE MITCHEL · CIK 0001201196 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,500 Underlying: Common Stock, par value $0.0001 · 25,500 shares Expires 2030-09-24 F1 · derivative.exercise_date: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following September 24, 2020, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| September 24, 2020 Filed Oct 16, 2020 23:00 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionRestricted Stock Units ("RSUs") · Derivative | 25,275 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-028540 · doc4.xml · derivative · entry 2 SAYARE MITCHEL · CIK 0001201196 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,275 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F2 · derivative.exercise_date: On June 25, 2020, the reporting person was granted 25,275 restricted stock units, which vested in full at the Company's 2020 annual meeting of stockholders on September 24, 2020. F2 · derivative.expiration_date: On June 25, 2020, the reporting person was granted 25,275 restricted stock units, which vested in full at the Company's 2020 annual meeting of stockholders on September 24, 2020. Read SEC document |
| September 24, 2020 Filed Oct 16, 2020 23:00 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 | 25,275 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-028540 · doc4.xml · nonDerivative · entry 1 SAYARE MITCHEL · CIK 0001201196 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,363 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 25, 2020 Filed Jun 30, 2020 01:48 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantRestricted Stock Units ("RSUs") · Derivative | 25,275 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-017824 · doc4.xml · derivative · entry 1 SAYARE MITCHEL · CIK 0001201196 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,275 Underlying: Common Stock · 25,275 shares Expires not disclosed F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F2 · derivative.exercise_date: The RSUs vest in full at the Company's 2020 annual meeting of stockholders, subject to the reporting person's continued service through the vesting date, and have no expiration date. F2 · derivative.expiration_date: The RSUs vest in full at the Company's 2020 annual meeting of stockholders, subject to the reporting person's continued service through the vesting date, and have no expiration date. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 22:22 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 30,000 | $0.00 Strike: $2.60 | $0.00 |
DisclosureSEC source: 0001012975-19-000041 · edgar.xml · derivative · entry 1 SAYARE MITCHEL · CIK 0001201196 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock, par value $0.0001 · 30,000 shares Expires 2029-01-02 F1 · derivative.exercise_date: The option becomes vested and exercisable in two equal installments on February 28, 2019 and August 30, 2019, in each case, generally subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| April 05, 2018 Filed Apr 7, 2018 00:27 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 35,000 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0001012975-18-000335 · edgar.xml · derivative · entry 1 SAYARE MITCHEL · CIK 0001201196 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock, par value $0.0001 · 35,000 shares Expires 2028-04-05 F1 · derivative.exercise_date: Fifty percent of the option will become vested and exercisable on June 30, 2018 and the remaining 50% of the option will vest and become exercisable on December 31, 2018. Read SEC document |
| December 29, 2017 Filed Jan 3, 2018 21:54 UTC | Altimmune, Inc. ALT · Entity 5349 | PurchaseCommon Stock, par value $0.0001 | 5,100 | $1.95 | $9,962.85 |
DisclosureSEC source: 0001012975-18-000023 · edgar.xml · nonDerivative · entry 1 SAYARE MITCHEL · CIK 0001201196 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 32,650 F1 · price: The price reflected is the weighted-average purchase price for shares purchased. The range of purchase prices for the transactions reported was $1.91 to $1.98 per share. The Reporting Person undertakes to provide, upon request by the Issuer, any security holder of the Issuer, or the SEC staff, full information regarding the number of shares purchased at each separate price. F2 · ownership.nature: The shares of Common Stock are owned directly by the Mitchel Sayare 2010 Trust. The Reporting Person, as sole trustee of the Mitchel Sayare 2010 Trust, may be deemed to be the beneficial owner of the securities held by the Mitchel Sayare 2010 Trust. The Reporting Person disclaims beneficial ownership of the securities held by the Mitchel Sayare 2010 Trust except to the extent of his pecuniary interest therein. Read SEC document |
| October 13, 2017 Filed Oct 18, 2017 00:24 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 20,000 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001012975-17-000771 · edgar.xml · derivative · entry 1 SAYARE MITCHEL · CIK 0001201196 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock, par value $0.0001 · 20,000 shares Expires 2027-10-13 Read SEC document |
| November 22, 2016 Filed Nov 23, 2016 21:47 UTC | Altimmune, Inc. PIP · Entity 5349 | Exercise / conversionStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.20 | $0.00 |
DisclosureSEC source: 0001144204-16-136387 · v453826_4.xml · derivative · entry 20 SAYARE MITCHEL · CIK 0001201196 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2026-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 22, 2016 Filed Nov 23, 2016 21:47 UTC | Altimmune, Inc. PIP · Entity 5349 | Exercise / conversionStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.69 | $0.00 |
DisclosureSEC source: 0001144204-16-136387 · v453826_4.xml · derivative · entry 19 SAYARE MITCHEL · CIK 0001201196 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2025-08-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 22, 2016 Filed Nov 23, 2016 21:47 UTC | Altimmune, Inc. PIP · Entity 5349 | Exercise / conversionStock option (right to buy) · Derivative | 18,361 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0001144204-16-136387 · v453826_4.xml · derivative · entry 18 SAYARE MITCHEL · CIK 0001201196 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,361 shares Expires 2024-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 22, 2016 Filed Nov 23, 2016 21:47 UTC | Altimmune, Inc. PIP · Entity 5349 | Exercise / conversionStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.51 | $0.00 |
DisclosureSEC source: 0001144204-16-136387 · v453826_4.xml · derivative · entry 17 SAYARE MITCHEL · CIK 0001201196 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2024-06-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 22, 2016 Filed Nov 23, 2016 21:47 UTC | Altimmune, Inc. PIP · Entity 5349 | Exercise / conversionStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001144204-16-136387 · v453826_4.xml · derivative · entry 16 SAYARE MITCHEL · CIK 0001201196 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2023-06-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 22, 2016 Filed Nov 23, 2016 21:47 UTC | Altimmune, Inc. PIP · Entity 5349 | Exercise / conversionStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0001144204-16-136387 · v453826_4.xml · derivative · entry 15 SAYARE MITCHEL · CIK 0001201196 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2022-06-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 22, 2016 Filed Nov 23, 2016 21:47 UTC | Altimmune, Inc. PIP · Entity 5349 | Exercise / conversionStock option (right to buy) · Derivative | 52,139 | $0.00 Strike: $2.67 | $0.00 |
DisclosureSEC source: 0001144204-16-136387 · v453826_4.xml · derivative · entry 14 SAYARE MITCHEL · CIK 0001201196 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 52,139 shares Expires 2021-07-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 22, 2016 Filed Nov 23, 2016 21:47 UTC | Altimmune, Inc. PIP · Entity 5349 | Exercise / conversionStock option (right to buy) · Derivative | 60,000 | $0.00 Strike: $2.67 | $0.00 |
DisclosureSEC source: 0001144204-16-136387 · v453826_4.xml · derivative · entry 13 SAYARE MITCHEL · CIK 0001201196 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,000 shares Expires 2021-07-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 22, 2016 Filed Nov 23, 2016 21:47 UTC | Altimmune, Inc. PIP · Entity 5349 | Exercise / conversionStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.60 | $0.00 |
DisclosureSEC source: 0001144204-16-136387 · v453826_4.xml · derivative · entry 12 SAYARE MITCHEL · CIK 0001201196 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2020-06-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 22, 2016 Filed Nov 23, 2016 21:47 UTC | Altimmune, Inc. PIP · Entity 5349 | Exercise / conversionStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.52 | $0.00 |
DisclosureSEC source: 0001144204-16-136387 · v453826_4.xml · derivative · entry 11 SAYARE MITCHEL · CIK 0001201196 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2020-04-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 22, 2016 Filed Nov 23, 2016 21:47 UTC | Altimmune, Inc. PIP · Entity 5349 | Exercise / conversionCommon Stock, $0.0001 par value per share | 20,000 | $2.20 | $44,000.00 |
DisclosureSEC source: 0001144204-16-136387 · v453826_4.xml · nonDerivative · entry 10 SAYARE MITCHEL · CIK 0001201196 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 22, 2016 Filed Nov 23, 2016 21:47 UTC | Altimmune, Inc. PIP · Entity 5349 | Exercise / conversionCommon Stock, $0.0001 par value per share | 20,000 | $1.69 | $33,800.00 |
DisclosureSEC source: 0001144204-16-136387 · v453826_4.xml · nonDerivative · entry 9 SAYARE MITCHEL · CIK 0001201196 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 22, 2016 Filed Nov 23, 2016 21:47 UTC | Altimmune, Inc. PIP · Entity 5349 | Exercise / conversionCommon Stock, $0.0001 par value per share | 18,361 | $1.81 | $33,233.41 |
DisclosureSEC source: 0001144204-16-136387 · v453826_4.xml · nonDerivative · entry 8 SAYARE MITCHEL · CIK 0001201196 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 22, 2016 Filed Nov 23, 2016 21:47 UTC | Altimmune, Inc. PIP · Entity 5349 | Exercise / conversionCommon Stock, $0.0001 par value per share | 20,000 | $1.51 | $30,200.00 |
DisclosureSEC source: 0001144204-16-136387 · v453826_4.xml · nonDerivative · entry 7 SAYARE MITCHEL · CIK 0001201196 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,139 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 22, 2016 Filed Nov 23, 2016 21:47 UTC | Altimmune, Inc. PIP · Entity 5349 | Exercise / conversionCommon Stock, $0.0001 par value per share | 20,000 | $1.64 | $32,800.00 |
DisclosureSEC source: 0001144204-16-136387 · v453826_4.xml · nonDerivative · entry 6 SAYARE MITCHEL · CIK 0001201196 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,139 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 22, 2016 Filed Nov 23, 2016 21:47 UTC | Altimmune, Inc. PIP · Entity 5349 | Exercise / conversionCommon Stock, $0.0001 par value per share | 20,000 | $1.45 | $29,000.00 |
DisclosureSEC source: 0001144204-16-136387 · v453826_4.xml · nonDerivative · entry 5 SAYARE MITCHEL · CIK 0001201196 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,139 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 22, 2016 Filed Nov 23, 2016 21:47 UTC | Altimmune, Inc. PIP · Entity 5349 | Exercise / conversionCommon Stock, $0.0001 par value per share | 52,139 | $2.67 | $139,211.13 |
DisclosureSEC source: 0001144204-16-136387 · v453826_4.xml · nonDerivative · entry 4 SAYARE MITCHEL · CIK 0001201196 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,139 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 22, 2016 Filed Nov 23, 2016 21:47 UTC | Altimmune, Inc. PIP · Entity 5349 | Exercise / conversionCommon Stock, $0.0001 par value per share | 60,000 | $2.67 | $160,200.00 |
DisclosureSEC source: 0001144204-16-136387 · v453826_4.xml · nonDerivative · entry 3 SAYARE MITCHEL · CIK 0001201196 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 22, 2016 Filed Nov 23, 2016 21:47 UTC | Altimmune, Inc. PIP · Entity 5349 | Exercise / conversionCommon Stock, $0.0001 par value per share | 20,000 | $1.60 | $32,000.00 |
DisclosureSEC source: 0001144204-16-136387 · v453826_4.xml · nonDerivative · entry 2 SAYARE MITCHEL · CIK 0001201196 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 22, 2016 Filed Nov 23, 2016 21:47 UTC | Altimmune, Inc. PIP · Entity 5349 | Exercise / conversionCommon Stock, $0.0001 par value per share | 20,000 | $1.52 | $30,400.00 |
DisclosureSEC source: 0001144204-16-136387 · v453826_4.xml · nonDerivative · entry 1 SAYARE MITCHEL · CIK 0001201196 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.